Fridkin SK, Hageman J, McDougal LK, Mohammed J, Jarvis WR, Perl TM, Tenover FC; Vancomycin-Intermediate Staphylococcus aureus Epidemiology Study Group. Epidemiological and microbiological char- acterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis. 2003;36:429 439. doi: 10.1086/346207. 140. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of van- comycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012;54:755 771. doi: 10.1093/cid/cir935. 141. Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O Sullivan MV, Anderson TL, Roberts SA, Gao W, Christiansen KJ, Coombs GW, Johnson PD, Howden BP. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacte- remia and high vancomycin minimum inhibitory concentrations. J Infect Dis. 2011;204:340 347. doi: 10.1093/infdis/jir270. 142. Cervera C, Casta eda X, de la Maria CG, del Rio A, Moreno A, Soy D, Pericas JM, Falces C, Armero Y, Almela M, Ninot S, Pare JC, Mestres CA, Gatell JM, Marco F, Miro JM; Hospital Clinic Endocarditis Study Group. Effect of vancomycin minimal inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus endocarditis. Clin Infect Dis. 2014;58:1668 1675. doi: 10.1093/cid/ciu183. 143. Anguera I, Del R o A, Mir JM, Mat nez-Lacasa X, Marco F, Gum JR, Quaglio G, Claramonte X, Moreno A, Mestres CA, Mauri E, Azqueta M, Benito N, Garc a-de la Mar a C, Almela M, Jim nez-Exp sito MJ, Sued O, De Lazzari E, Gatell JM; Hospital Clinic Endocarditis Study Group. Staphylococcus lugdunensis infective endocarditis: description of 10 cases and analysis of native valve, prosthetic valve, and pacemaker Baddour et al Infective Endocarditis in Adults 1481 lead endocarditis clinical profiles. Heart. 2005;91:e10. doi: 10.1136/ hrt.2004.040659. 144. 